Eunice Wang

Join Dr. Selina Luger and a panel of AML experts: Dr. Andrew Wei, a researcher on azacitidine and venetoclax at the Peter MacCallum Cancer Centre; Dr. Gail Roboz, who specializes in maintenance therapy at Weill Cornell Medicine; Dr. Eunice Wang, who addresses secondary AML challenges at Roswell Park; and Dr. Courtney DiNardo, focused on targeted therapies at MD Anderson. They discuss groundbreaking outpatient therapies, the complexities of maintenance strategies, and advancements in differentiating agents that may improve patient outcomes.

Dr. Eunice Wang, a leading expert in AML and chief of the leukemia service at Roswell Park, joins Dr. Rahul Banerjee for a deep dive into the complexities of leukemia treatment. They discuss the biology and risk profile of NPM1, and how menin inhibitors function, shedding light on the COMET-001 trial for ziftomenib. With a 33% response rate, Wang highlights its promise in treating relapsed AML. The duo also explores combinations of ziftomenib with other therapies, and details the importance of differentiating syndrome management in practice.

Dr. Eunice Wang, a leading hematologist-oncologist at Roswell Park Comprehensive Cancer Center, shares her expertise on the recent FDA approval of Ziftomenib for NPM1-mutant acute myeloid leukemia (AML). She discusses the promising results from the KOMET-001 trial, highlighting a nearly 30% response rate and improved survival for patients. Dr. Wang dives into the mechanism of action of menin inhibitors, management of side effects, and the importance of patient sequencing. She also contrasts Ziftomenib with other treatments, paving the way for future therapies.